Plasma levels of inflammatory chemokines in patients with polypoidal choroidal vasculopathy.
Aged
Biomarkers
/ blood
Case-Control Studies
Chemokines
/ blood
Choroid
/ blood supply
Choroid Diseases
/ blood
Female
Fluorescein Angiography
/ methods
Fundus Oculi
Humans
Inflammation
/ blood
Male
Ophthalmoscopy
/ methods
Polyps
/ blood
Prospective Studies
Slit Lamp Microscopy
Tomography, Optical Coherence
/ methods
CX3CL1
Chemokines
Fractalkine
Plasma
Polypoidal choroidal vasculopathy
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
27
06
2019
accepted:
11
10
2019
pubmed:
5
11
2019
medline:
1
4
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
Chemokines are a group of cytokines that guide immune cell migration. We studied plasma levels of inflammatory chemokines in patients with polypoidal choroidal vasculopathy (PCV) and compared with healthy age-matched control individuals. This was a clinic-based prospective case-control study of participants (n = 60) with either PCV (n = 26) or age-matched healthy controls (n = 34). We sampled fresh venous blood and isolated plasma for analysis. We used U-PLEX Human Assays to quantify concentrations of the inflammatory chemokines MCP-1/CCL2, RANTES/CCL5, eotaxin/CCL11, IP-10/CXCL10 and fractalkine/CX3CL1. Plasma levels of fractalkine was significantly higher in patients with PCV when compared to healthy controls (mean ± SD: 7291 ± 2461 pg/ml versus 5879 ± 2001 pg/ml; p = 0.021). Plasma levels of MCP-1 (p = 0.846), RANTES (p = 0.288), eotaxin (p = 0.496) and IP-10 (p = 0.352) did not differ significantly between the groups. To evaluate possible biomarker quality of fractalkine, we used a ROC analysis and found a positive but weak discriminatory ability (AUC = 0.68). Patients with PCV have a higher plasma level of fractalkine. Although the differences do not possess strong biomarker qualities, they inform on disease processes of a poorly understood disease and suggest that the fractalkine-CX3CR1 axis may be involved. As this study did not investigate local chemokine concentrations, we are unable to confirm or disprove any local chorioretinal interaction, and our findings should be interpreted with such caution.
Substances chimiques
Biomarkers
0
Chemokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-389Subventions
Organisme : Danish Eye Research Foundation
Organisme : Fight for Sight Denmark
Organisme : Velux Foundation
Organisme : Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
Informations de copyright
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Agawa T, Usui Y, Wakabayashi Y et al. (2014): Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina 34: 1811-1818.
Anand A, Sharma NK, Gupta A, Prabhakar S, Sharma SK, Singh R & Gupta PK (2012): Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PLoS ONE 7: e49905.
Cackett P, Yeo I, Cheung CM et al. (2011): Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology 118: 846-852.
Call DR, Nemzek JA, Ebong SJ, Bolgos GL, Newcomb DE & Remick DG (2001): Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol 158: 715-721.
Clover AJ, Kumar AH & Caplice NM (2011): Deficiency of CX3CR1 delays burn wound healing and is associated with reduced myeloid cell recruitment and decreased sub-dermal angiogenesis. Burns 37: 1386-1393.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
Combadière C, Feumi C, Raoul W et al. (2007): CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 117: 2920-2928.
Falk MK, Singh A, Faber C, Nissen MH, Hviid T & Sørensen TL (2014a): Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case-control study. BMC Ophthalmol 14: 22.
Falk MK, Singh A, Faber C, Nissen MH, Hviid T & Sørensen TL (2014b): CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD. PLoS ONE 9: e112473.
Falk MK, Singh A, Faber C, Nissen MH, Hviid T & Sørensen TL (2014c): Dysregulation of CXCR3 expression on peripheral blood leukocytes in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 55: 4050-4056.
Gharehbagh SS, Subhi Y & Sørensen TL (2018): Efficacy of aflibercept for polypoidal choroidal vasculopathy in Caucasians. Acta Ophthalmol 96: e94-e95.
Grunin M, Burstyn-Cohen T, Hagbi-Levi S, Peled A & Chowers I (2012): Chemokine receptor expression in peripheral blood monocytes from patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 53: 5292-5300.
Hu J, Leng X, Hu Y, Atik A, Song X, Li Z, Liu Y & Lu L (2016): The features of inflammation factors concentrations in aqueous humor of polypoidal choroidal vasculopathy. PLoS ONE 11: e0147346.
Iijima H, Imai M, Gohdo T & Tsukahara S (1999): Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 127: 301-305.
Ishida Y, Gao JL & Murphy PM (2008): Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol 180: 569-579.
Kikuchi M, Nakamura M, Ishikawa K et al. (2007): Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 114: 1722-1727.
Kleiner RC, Brucker AJ & Johnston RL (1990): The posterior uveal bleeding syndrome. Retina 10: 9-17.
Kumar S, Nakashizuka H, Jones A et al. (2017): Proteolytic degradation and inflammation play critical roles in polypoidal choroidal vasculopathy. Am J Pathol 187: 2841-2857.
Kumar A, Kumawat D, Sundar MD et al. (2019): Polypoidal choroidal vasculopathy: a comprehensive clinical update. Ther Adv Ophthalmol 11: 2515841419831152.
Lafaut BA, Aisenbrey S, Van den Broecke C, Bartz-Schmidt KU & Heimann K (2000): Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlation. Retina 20: 650-654.
Landsman L, Bar-On L, Zernecke A et al. (2009): CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113: 963-972.
Lorentzen TD, Subhi Y & Sørensen TL (2018a): Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis. Retina 38: 2363-2371.
Lorentzen TD, Subhi Y & Sørensen TL (2018b): Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naïve exudative age-related macular degeneration. Acta Ophthalmol 96: 475-480.
Mo FM, Proia AD, Johnson WH, Cyr D & Lashkari K (2010): Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 4226-4236.
Moussa K, Bloomer MM, Schwartz DM, Pan CK, Toy BC, Crawford JB & Afshar AR (2017): Polypoidal choroidal vasculopathy: a clinicopathologic study. Retin Cases Brief Rep 11(Suppl 1): S128-S131.
Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R & Yuzawa M (2008): Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 49: 4729-4737.
Okubo A, Sameshima M, Uemura A, Kanda S & Ohba N (2002): Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 86: 1093-1098.
Raoul W, Auvynet C, Camelo S, Guillonneau X, Feumi C, Combadière C & Sennlaub F (2010): CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation 7: 87.
Rifai N & Ridker PM (2001): Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 47: 28-30.
Sakamoto S, Takahashi H, Tan X et al. (2018): Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol 102: 448-454.
Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, Mukaida N, Kaneko S & Wada T (2011): Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res 34: 747-752.
Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J & Orlach DA (1995): Indocyanine green video angiography of idiopathic polypoidal choroidal vasculopathy. Retina 15: 100-110.
Stern RM, Zakov ZN, Zegarra H & Gutman FA (1985): Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol 100: 560-569.
Subhi Y & Sørensen TL (2016): Physical activity patterns in patients with early and late age-related macular degeneration. Dan Med J 63: A5303.
Subhi Y, Singh A, Falk MK & Sørensen TL (2014): In patients with neovascular age-related macular degeneration, physical activity may influence C-reactive protein levels. Clin Ophthalmol 8: 15-21.
Subhi Y, Krogh Nielsen M, Molbech CR & Sørensen TL (2018): Altered proportion of CCR2 + and CX3CR1 + circulating monocytes in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Clin Exp Ophthalmol 46: 661-669.
Subhi Y, Krogh Nielsen M, Molbech CR, Krüger Falk M, Singh A, Hviid TVF, Nissen MH & Sørensen TL (2019a): Association of CD11b+ monocytes and anti-vascular endothelial growth factor injections in treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. JAMA Ophthalmol 137: 515-522.
Subhi Y, Krogh Nielsen M, Molbech CR, Oishi A, Singh A, Nissen MH & Sørensen TL (2019b): Polypoidal choroidal vasculopathy associate with diminished regulatory T cells that are polarized into a T helper 2-like phenotype. Invest Ophthalmol Vis Sci 60: 2583-2590.
Teo KYC, Gillies M & Fraser-Bell S (2018): The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy: a subtype of neovascular age-related macular degeneration. Int J Mol Sci 19: E2611.
Tso MOM, Suarez MJ & Eberhart CG (2017): Pathologic study of early manifestations of polypoidal choroidal vasculopathy and pathogenesis of choroidal neovascularization. Am J Ophthalmol Case Rep 11: 176-180.
Wong CW, Wong TY & Cheung CM (2015): Polypoidal choroidal vasculopathy in Asians. J Clin Med 4: 782-821.
Yannuzzi LA. Idiopathic polypoidal choroidal vasculopathy. Presented at The Macula Society Meeting. Miami, FL, February 5, 1982.
Yannuzzi LA, Sorenson J, Spaide RF & Lipson B (1990): Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10: 1-8.